Biotech Values

[ThomasS]

NVS/MNTA: Dew, did you happen to listen to the NVS CC? Any word re MNTA?
From the NVS PR: "Sandoz
A response was submitted in September to the FDA responding to questions from the US agency for the development project enoxaparin, a technologically enabled generic version of Lovenox® (enoxaparin sodium) being developed with Momenta. This medicine is a low-molecular-weight heparin marketed by Sanofi-aventis and used for the prevention and treatment of deep vein thrombosis and several cardiovascular conditions. A launch of this product in the US is expected during 2009."



"Illegitimacy is something we should talk about in terms of not having it."

- Dan Quayle